Drug interactions
Lorlatinib + Vorapaxar
Severity: Moderate
Lorlatinib and Vorapaxar: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib may induce CYP3A4 and reduce vorapaxar exposure, weakening antiplatelet effect. Vorapaxar labeling advises avoiding strong CYP3A inducers, and lorlatinib is a moderate inducer.
What this interaction means in plain words
Lorlatinib and Vorapaxar can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Induction of CYP3A4 by lorlatinib increases vorapaxar clearance.
What to do
Consider alternative antiplatelet therapy, and monitor for thrombotic events if both are used.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Vorapaxar, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Lorlatinib with Vorapaxar?
MediHelp rates the interaction as moderate. Lorlatinib and Vorapaxar can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib may induce CYP3A4 and reduce vorapaxar exposure, weakening antiplatelet effect. Vorapaxar labeling advises avoiding strong CYP3A inducers, and lorlatinib is a moderate inducer.
How serious is the interaction between Lorlatinib and Vorapaxar?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Consider alternative antiplatelet therapy, and monitor for thrombotic events if both are used.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
